Phase 2, Phase 3 Recruiting Network
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protoco…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03851445
Sites in Nebraska: - Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Nebraska Hematology and Oncology — Lincoln, Nebraska
- Cancer Partners of Nebraska — Lincoln, Nebraska
- Faith Regional Health Services Carson Cancer Center — Norfolk, Nebraska
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Nebraska: - Nebraska Medicine-Bellevue — Bellevue, Nebraska
- Nebraska Medicine-Village Pointe — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Nebraska: - Local Institution - 007-590D — Grand Island, Nebraska
- Local Institution - 007-590A — Omaha, Nebraska
- Local Institution - 007-590B — Omaha, Nebraska
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy — Omaha, Nebraska
- Local Institution - 007-590C — Papillion, Nebraska
Phase 3 Recruiting Industry
The purpose of this study is to understand if PF-08046054 alone works well compared to standard-of-care docetaxel alone in participants with non-small cell lung cancer (NSCLC) with PD-L1 expression greater than or equal to 1% and had cance…
Sponsor: Pfizer
NCT ID: NCT07144280
Sites in Nebraska: - Nebraska Medicine-Bellevue Medical Center — Bellevue, Nebraska
- Nebraska Medicine — Omaha, Nebraska
- Nebraska Medicine - Village Pointe — Omaha, Nebraska
- University Of Nebraska Medical Center — Omaha, Nebraska
Phase 3 Recruiting Industry
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Ar…
Sponsor: OSE Immunotherapeutics
NCT ID: NCT06472245
Sites in Nebraska: - Nebraska Hematology-Oncology - Revive Research Institute LLC — Lincoln, Nebraska
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Nebraska: - Mary Lanning Healthcare (MLH) - Morrison Cancer Center (MCC) — Hastings, Nebraska
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07554339
Sites in Nebraska: - NHO Revive Research Institute LLC ( Site 0118) — Lincoln, Nebraska
Phase 2 Recruiting Network
This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tis…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05642572
Sites in Nebraska: - CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
- Alegent Health Bergan Mercy Medical Center — Omaha, Nebraska
- Alegent Health Lakeside Hospital — Omaha, Nebraska
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska
Phase 2 Recruiting Industry
The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combinati…
Sponsor: AstraZeneca
NCT ID: NCT05061550
Sites in Nebraska: - Research Site — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and efficacy of Imzokitug in combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as first-line treatment for participants with Local…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07680764
Sites in Nebraska: - Nebraska Cancer Specialists — Grand Island, Nebraska
- Oncology Hematology West PC — Omaha, Nebraska
Phase 2 Recruiting Industry
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monot…
Sponsor: Genmab
NCT ID: NCT07288177
Sites in Nebraska: - Nebraska Hematology-Oncology — Lincoln, Nebraska
Phase 2 Recruiting Federal
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Sponsor: VA Office of Research and Development
NCT ID: NCT06275360
Sites in Nebraska: - Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE — Omaha, Nebraska
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoper…
Sponsor: Radiopharm Theranostics, Ltd
NCT ID: NCT07189871
Sites in Nebraska: - Nebraska Cancer Specialists — Omaha, Nebraska
- XCancer — Omaha, Nebraska
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Nebraska: - Nebraska Cancer Center Oncology Hematology West P.C. — Omaha, Nebraska
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Nebraska: - CHI Health Saint Francis — Grand Island, Nebraska
- Nebraska Cancer Specialists/Oncology Hematology West PC — Grand Island, Nebraska
- CHI Health Good Samaritan — Kearney, Nebraska
- Saint Elizabeth Regional Medical Center — Lincoln, Nebraska
- Alegent Health Immanuel Medical Center — Omaha, Nebraska
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Nebraska: - CHI Health Good Samaritan — Kearney, Nebraska
Recruiting Industry
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this m…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT04165798
Sites in Nebraska: - Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) — Omaha, Nebraska
NA Recruiting Industry
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer di…
Sponsor: Pack Health
NCT ID: NCT05349227
Sites in Nebraska: - University of Nebraska Medical Center — Omaha, Nebraska